Glioma remains one of the most difficult cancers to treat. Even with maximal safe surgery followed by radiotherapy and temozolomide chemotherapy, survival for many patients with high-grade disease rarely extends beyond 15 to 18 months. A review published in the Chinese Medical Journal argues that this bleak outlook cannot be explained by tumor-cell genetics alone. Instead, glioma behaves as an ecosystem in which malignant cells continuously exchange signals with immune cells, neurons, astrocytes, blood vessels and lymphatic structures. These interactions create a protective environment that supports tumor growth, invasion, metabolic adaptation and resistance to treatment.
The review, titled “Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives,” describes the tumor microenvironment as an active biological network rather than a passive structure surrounding cancer cells. Glioma cells release cytokines, chemokines, growth factors and extracellular-matrix-modifying enzymes that reshape neighboring cells. In response, immune and stromal cells alter their behavior in ways that can benefit the tumor. The result is a paradoxical state sometimes described as “inflammation without immunity”: immune cells accumulate in the tumor, but many become functionally suppressed and incapable of mounting an effective antitumor response.
Resident microglia, the brain’s innate immune sentinels, are among the first cells to be reprogrammed. Glioma-derived molecules such as Versican can push microglia toward a pro-tumorigenic phenotype. Once polarized, these cells may support invasion through matrix metalloproteinase-14, or MMP14, and other mediators including stress-inducible protein 1, secreted phosphoprotein 1 and epidermal growth factor. They can also contribute to immune suppression by expressing programmed death-ligand 1, or PD-L1, and transforming growth factor beta. These signals weaken local T-cell activity while helping malignant cells move through the surrounding brain tissue.
Circulating monocytes provide another major source of tumor-associated macrophages. Gliomas recruit these cells through chemokine systems such as the CCL2/CCR2 and CSF1/CSF1R pathways. After entering the tumor, monocytes differentiate into macrophages with a broad functional spectrum. A minority may retain inflammatory properties and release interleukin-1 beta, interleukin-27 and tumor necrosis factor. However, the review emphasizes that most adopt an anti-inflammatory and immunosuppressive state marked by PD-L1, transforming growth factor beta, interleukin-10 and arginase 1. These macrophages also promote blood-vessel formation through vascular endothelial growth factor and epidermal growth factor, while MMP2 helps remodel the extracellular matrix and opens pathways for invasion.
Other myeloid populations further reinforce this immune barrier. Neutrophils can be drawn into the glioma microenvironment through interleukin-8 signaling, where they may encourage additional recruitment of neutrophils and monocytes. Their expression of arginase 1 can deprive T cells of essential metabolic resources and restrict their ability to proliferate. Yet the review highlights an important exception: hybrid dendritic-like neutrophils may possess antitumor properties by presenting signals that prime T-cell cytotoxicity and support immune memory. Myeloid-derived suppressor cells, or MDSCs, are recruited through CCL2 and stromal cell-derived factor 1 alpha, also known as SDF-1α. They suppress adaptive immunity using arginase 1, inducible nitric oxide synthase, PD-L1 and transforming growth factor beta.
Dendritic cells, which normally function as professional antigen-presenting cells, are also undermined by the glioma environment. Tumor-derived vascular endothelial growth factor, interleukin-6 and interleukin-10 can interfere with dendritic-cell maturation and reduce their capacity to process and present tumor antigens. Without effective antigen presentation, T cells are not properly activated against malignant cells. Even when T cells do enter the tumor, they frequently encounter an environment dominated by inhibitory signals. Repeated engagement between PD-1 on T cells and PD-L1 on tumor or immune cells can drive exhaustion or apoptosis, while transforming growth factor beta and indoleamine 2,3-dioxygenase 1 further suppress T-cell metabolism and function. This helps explain why immune infiltration does not necessarily translate into tumor control.
The neural nature of the brain adds another layer of complexity. Research summarized in the review shows that glioma cells can form functional excitatory synapses with neurons. Through these connections, neuronal activity and neurotransmitters such as glutamate can directly stimulate tumor-cell signaling and growth. Glioma cells may also exploit gamma-aminobutyric acid and neurotrophic factors, including neuroligin-3, brain-derived neurotrophic factor, insulin-like growth factor 1 and semaphorin 4F. Neuroligin-3 is particularly important because neuronal activity can trigger its release, activating growth programs in glioma cells. This creates a feed-forward loop in which active neural circuits promote tumor expansion, while the expanding tumor becomes increasingly integrated into the surrounding brain network.
Astrocytes and oligodendrocyte-lineage cells are similarly drawn into the tumor-supporting system. Reactive astrocytes can communicate with glioma cells through gap junctions, allowing direct exchange of ions and signaling molecules. Additional interactions involving interleukin-11 and its receptor, as well as annexin A1-related signaling, may promote invasion and suppress T-cell immunity. Although the review gives less emphasis to oligodendrocyte-lineage cells, it identifies them as additional participants in glioma progression, with potential roles in angiogenesis and immune escape. Together, these findings challenge the traditional view that the malignant cell is the only biologically relevant target inside the brain.
The vascular system provides both nutrients and a route for tumor dissemination. Glioma-associated endothelial cells respond to vascular endothelial growth factor and fibroblast growth factor, driving the formation of abnormal blood vessels. These vessels are often tortuous, structurally fragile and poorly organized. Their dysfunction disrupts the blood-brain barrier, increasing the movement of peripheral immune cells into the tumor while simultaneously creating profound therapeutic obstacles. Abnormal perfusion can produce regions of hypoxia and impaired drug distribution, meaning that a medicine may reach some tumor compartments but fail to penetrate others. Lymphatic endothelial cells may also participate directly in tumor progression through the CCL21/CCR7 signaling axis, adding another route of communication between glioma cells and the surrounding tissue.
The review argues that these interconnected mechanisms demand a broader therapeutic strategy. Blocking tumor-cell proliferation alone may not be enough if microglia and macrophages remain immunosuppressive, neuronal activity continues to stimulate growth, and abnormal vessels prevent adequate drug delivery. Potential approaches include reprogramming tumor-associated macrophages, inhibiting monocyte recruitment through the CCL2/CCR2 or CSF1/CSF1R axes, targeting MDSCs, restoring dendritic-cell function and combining immune checkpoint blockade with methods that reverse T-cell exhaustion. Interfering with neuron-glioma synapses, neuroligin-3 signaling, glutamatergic stimulation or astrocyte-mediated communication could provide additional ways to disrupt the tumor’s neural support system. The authors present the glioma microenvironment not only as the central engine of therapeutic resistance but also as a source of new vulnerabilities. By dismantling the ecosystem that protects malignant cells, future treatments may move beyond attacking the tumor in isolation and instead disable the biological network that allows it to survive.
Subject of Research: Glioma tumor microenvironment and cellular crosstalk
Article Title: Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives
News Publication Date: 15 June 2026
Web References: https://doi.org/10.1097/CM9.0000000000004151
References: Zhao L. “Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives.” Chinese Medical Journal. DOI: 10.1097/CM9.0000000000004151
Image Credits: Chinese Medical Journal
Keywords: glioma, brain cancer, tumor microenvironment, neuro-oncology, microglia, macrophages, immunosuppression, T-cell exhaustion, glioma immunotherapy, neuron-tumor communication, astrocytes, tumor-associated macrophages, blood-brain barrier, cancer neuroscience
Tags: cellular crosstalk in gliomaglioma cytokine and chemokine signalingglioma immune evasion mechanismsglioma invasion and progressionglioma metabolic adaptationglioma microenvironment targetingglioma resistance to therapyglioma tumor microenvironmentimmune suppression in gliomamicroglia reprogramming in gliomanovel glioma treatment strategiestumor-immune cell interactions
